EyeGate Pharmaceuticals Inc buy melinda
Startpreis
17.11.18
/
50%
6,50 €
Kursziel
28.11.18
0,90 €
Rendite (%)
14,58 %
Endpreis
28.11.18
7,44 €
Zusammenfassung
Diese Einschätzung wurde am 28.11.18 mit einem Endkurs von 7,44 € beendet. Mit einer Rendite von 14,58 % entwickelte sich die Einschätzung BUY ganz nach Plan. melinda hat 50% Zuversicht bei dieser Einschätzung
Finanztrends
Rendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| EyeGate Pharmaceuticals Inc | - | - | - | - |
| iShares Core DAX® | -0,26 % | 0,30 % | 15,65 % | 15,94 % |
| iShares Nasdaq 100 | 2,96 % | 4,66 % | 32,00 % | 57,19 % |
| iShares Nikkei 225® | 1,22 % | -2,16 % | 6,67 % | 4,29 % |
| iShares S&P 500 | 1,73 % | 2,81 % | 25,60 % | 48,53 % |
Kommentare von melinda zu dieser Einschätzung
In der Diskussion EyeGate Pharmaceuticals Inc diskutieren
Eyegate Pharmaceuticals (EYEG) PT Set à 6,00 $ par HC Wainwright
Develops pharmaceutical products to treat eye diseases
EyeGate Pharma is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes EGP-437 and Ocular Bandage Gel (OBG).
OBG is a topically-applied eye drop formulation that is being developed under the 510k De Novo path for devices submitted for marketing clearance to the U.S. FDA. The company was founded in 1998 and is headquartered in Waltham, MA.
EyeGate Pharma is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes EGP-437 and Ocular Bandage Gel (OBG).
OBG is a topically-applied eye drop formulation that is being developed under the 510k De Novo path for devices submitted for marketing clearance to the U.S. FDA. The company was founded in 1998 and is headquartered in Waltham, MA.
Nombre d'employés : 17 personnes.
(Vom Mitglied beendet)
Beendete Einschätzungen von melinda zu EyeGate Pharmaceuticals Inc
EyeGate Pharmaceuticals Inc
Startkurs
Kursziel
Rendite (%)
17,26 €
14.06.17
14.06.17
1,58 €
14.12.17
14.12.17
-4,59 %
14.12.17
14.12.17
EyeGate Pharmaceuticals Inc
Startkurs
Kursziel
Rendite (%)
26,65 €
01.05.17
01.05.17
2,26 €
22.05.17
22.05.17
4,03 %
22.05.17
22.05.17